BR112020008598A2 - cocristais, suas composições farmacêuticas e métodos de tratamento envolvendo os mesmos - Google Patents

cocristais, suas composições farmacêuticas e métodos de tratamento envolvendo os mesmos Download PDF

Info

Publication number
BR112020008598A2
BR112020008598A2 BR112020008598-7A BR112020008598A BR112020008598A2 BR 112020008598 A2 BR112020008598 A2 BR 112020008598A2 BR 112020008598 A BR112020008598 A BR 112020008598A BR 112020008598 A2 BR112020008598 A2 BR 112020008598A2
Authority
BR
Brazil
Prior art keywords
compound
cocrystal
formula
theta
pharmaceutical composition
Prior art date
Application number
BR112020008598-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Benjamin S. Lane
Chong-Hui Gu
Original Assignee
Agios Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals, Inc. filed Critical Agios Pharmaceuticals, Inc.
Publication of BR112020008598A2 publication Critical patent/BR112020008598A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/145Maleic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265Citric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112020008598-7A 2017-11-02 2018-11-02 cocristais, suas composições farmacêuticas e métodos de tratamento envolvendo os mesmos BR112020008598A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762580501P 2017-11-02 2017-11-02
US62/580,501 2017-11-02
PCT/US2018/058930 WO2019090059A1 (en) 2017-11-02 2018-11-02 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same

Publications (1)

Publication Number Publication Date
BR112020008598A2 true BR112020008598A2 (pt) 2021-01-26

Family

ID=64572453

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020008598-7A BR112020008598A2 (pt) 2017-11-02 2018-11-02 cocristais, suas composições farmacêuticas e métodos de tratamento envolvendo os mesmos

Country Status (17)

Country Link
US (3) US11345677B2 (enExample)
EP (1) EP3704101A1 (enExample)
JP (3) JP7335877B2 (enExample)
KR (2) KR20240166601A (enExample)
CN (2) CN118359585A (enExample)
AU (2) AU2018360827B2 (enExample)
BR (1) BR112020008598A2 (enExample)
CA (1) CA3081535A1 (enExample)
EA (1) EA202091112A1 (enExample)
IL (2) IL274123B2 (enExample)
MA (1) MA50526A (enExample)
MX (2) MX2020004513A (enExample)
PH (1) PH12020550462A1 (enExample)
SG (1) SG11202003612VA (enExample)
TW (2) TWI839131B (enExample)
UA (1) UA127380C2 (enExample)
WO (1) WO2019090059A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085832A1 (en) * 2019-11-22 2020-03-19 Agios Pharmaceuticals, Inc. Deuterated analogs of an organic compound
TW202227446A (zh) 2020-08-12 2022-07-16 美商施維雅製藥有限公司 有機化合物之固態形式
WO2023192565A1 (en) 2022-03-31 2023-10-05 Servier Pharmaceuticals Llc Methods of treating enhancing brain tumors using combination therapy
AR133332A1 (es) 2023-07-25 2025-09-17 Servier Lab Sales, cocristales, composiciones farmacéuticas de los mismos, y métodos de tratamiento que implican los mismos
WO2025060940A1 (zh) * 2023-09-18 2025-03-27 贝达药业股份有限公司 突变型idh抑制剂化合物及其盐的固体形式
EP4538262A1 (en) 2023-10-12 2025-04-16 Sandoz Ag Cocrystals of vorasidenib
WO2025168757A1 (en) 2024-02-09 2025-08-14 Les Laboratoires Servier Process for the preparation of vorasidenib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2815858C (en) * 2010-11-01 2018-10-16 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
AU2018360827A1 (en) 2020-05-14
IL274123B2 (en) 2024-01-01
SG11202003612VA (en) 2020-05-28
US20210198234A1 (en) 2021-07-01
TWI839131B (zh) 2024-04-11
KR102731624B1 (ko) 2024-11-19
CN111527076B (zh) 2024-03-12
MX2022014792A (es) 2023-01-16
EP3704101A1 (en) 2020-09-09
JP2021501766A (ja) 2021-01-21
EA202091112A1 (ru) 2020-07-23
WO2019090059A1 (en) 2019-05-09
US20220363661A1 (en) 2022-11-17
AU2018360827B2 (en) 2024-02-22
TW201930285A (zh) 2019-08-01
PH12020550462A1 (en) 2021-03-22
US20240343705A1 (en) 2024-10-17
JP7780576B2 (ja) 2025-12-04
AU2024203186A1 (en) 2024-05-30
TWI796377B (zh) 2023-03-21
JP7499377B2 (ja) 2024-06-13
CA3081535A1 (en) 2019-05-09
JP7335877B2 (ja) 2023-08-30
IL305426B1 (en) 2024-06-01
IL274123B1 (en) 2023-09-01
JP2024113028A (ja) 2024-08-21
CN118359585A (zh) 2024-07-19
IL305426A (en) 2023-10-01
US11851417B2 (en) 2023-12-26
CN111527076A (zh) 2020-08-11
IL274123A (en) 2020-06-30
MA50526A (fr) 2020-09-09
JP2023093666A (ja) 2023-07-04
US11345677B2 (en) 2022-05-31
KR20240166601A (ko) 2024-11-26
IL305426B2 (en) 2024-10-01
KR20200095480A (ko) 2020-08-10
MX2020004513A (es) 2020-09-17
UA127380C2 (uk) 2023-08-02
TW202337885A (zh) 2023-10-01

Similar Documents

Publication Publication Date Title
US11851417B2 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
IL301687A (en) Combined treatment for cancer
US12303512B2 (en) Therapeutically active compounds and their methods of use
US20250034109A1 (en) Salts, cocrystals, pharmaceutical compositions thereof, and methods of treatment involving the same
US20250041283A1 (en) Cocrystal of an idh1 inhibitor, process of preparation thereof, pharmaceutical compositions thereof, and methods of treatment involving the same
EA042081B1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA048730B1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
BR122025007379A2 (pt) Usos de compostos terapeuticamente ativos
EA050372B1 (ru) Терапевтически активные соединения и способы их применения
EP4291198A1 (en) Therapeutically active compounds and their methods of use

Legal Events

Date Code Title Description
B15V Prolongation of time limit allowed

Free format text: TENDO EM VISTA A PORTARIA INPI PR NO 120 DE 16/03/2020, PORTARIA INPI PR NO 161 DE 13/04/2020; PORTARIA INPI PR NO 166 DE 27/04/2020 E PORTARIA INPI PR NO 179 DE 11/05/2020, QUANTO A SUSPENSAO DOS PRAZOS VENCIDOS ENTRE 16/03/2020 A 31/05/2020, E PORTARIA INPI NO 334 DE 24/09/2020, QUANTO AOS PRAZOS VENCIDOS ENTRE 16/09/2020 A 25/09/2020, DEVOLVE-SE O PRAZO NESSE PEDIDO COM RELACAO A SOLICITACAO DO PEDIDO DE EXAME.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25A Requested transfer of rights approved

Owner name: LES LABORATOIRES SERVIER (FR)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/11/2018, OBSERVADAS AS CONDICOES LEGAIS